查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2045925

類風濕性關節炎診斷測試市場－全球產業規模、佔有率、趨勢、機會、預測：按測試類型、最終用戶、地區和競爭對手分類，2021-2031年

Rheumatoid Arthritis Diagnostic Tests Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Test Type, By End User, By Region & Competition, 2021-2031F
出版日期: | 出版商: TechSci Research | 英文 180 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

全球類風濕性關節炎診斷測試市場預計將從 2025 年的 33.1 億美元成長到 2031 年的 47.2 億美元，複合年成長率為 6.09%。

該市場涵蓋旨在檢測自體免疫標記和評估關節發炎的臨床檢測和影像技術，在確診和監測疾病進展方面發揮著至關重要的作用。這一成長主要受自體免疫疾病盛行率上升、老年人口增加以及臨床實踐中日益重視早期療育以預防不可逆關節損傷等因素驅動。根據關節炎基金會預測，到2025年，美國將有約130萬成年人患有類風濕性關節炎，凸顯了對有效篩檢工具的巨大需求。

市場概覽
預測期 2027-2031
市場規模：2025年 33.1億美元
市場規模：2031年 47.2億美元
複合年成長率：2026-2031年 6.09%
成長最快的細分市場 血清學檢測
最大的市場 北美洲

然而，開發中國家先進診斷設備的高成本構成了市場發展的一大障礙。專業檢測方法和先進成像系統的相關費用阻礙了這些技術在經濟資源有限的地區的廣泛應用。這一經濟障礙，加上診斷不具備標準生物標記的患者所面臨的挑戰，嚴重限制了全球市場的擴張。因此，在成本敏感地區進行全面檢測的難度仍然是該行業發展面臨的一大限制。

市場促進因素

診斷檢測市場的主要促進因素是類風濕性關節炎在全球日益成長的盛行率，這推動了對準確且擴充性的調查方法的需求。隨著自體免疫疾病發生率的上升，醫療基礎設施面臨越來越大的壓力，需要建立一個能夠在疾病早期階段識別疾病的診斷系統。延遲診斷對勞動年齡人口造成的嚴重健康和經濟影響進一步加劇了這種緊迫性。根據2025年6月發表在PLOS上的一篇報導，2021年全球勞動年齡人口中類風濕性關節炎病例達1188萬例，這凸顯了迫切需要便捷的血清學和影像學檢測方法來有效管理這一不斷成長的患者群體。

同時，免疫檢測技術的突破和新型生物標記的發現正在改變市場模式。這些突破提高了檢測靈敏度，並加速了個人化醫療的發展。將人工智慧 (AI) 和機器學習與傳統診斷方法結合，能夠更準確地預測治療反應，並做出更恰當的臨床決策。例如，Scipher Medicine 於 2025 年 6 月公佈了其基於人工智慧的類風濕關節炎 (RA) 反應策展人的結果，該計算器利用了約 1500 名患者的數據，旨在改進治療檢驗。這項技術發展勢頭得到了大量投資的支持，例如 Aqtual 在 2025 年完成的 3,100 萬美元 B 輪資金籌措，用於將其精準醫療解決方案商業化。

市場挑戰

開發中國家先進診斷工具的高昂成本是類風濕性關節炎診斷檢測市場擴張的主要障礙。專業檢測和尖端影像設備的價格往往超出這些地區醫療系統的預算，迫使醫療服務提供者依賴基本的臨床評估，而非精準的篩檢方法。這種價格差異限制了先進檢測套組的銷量，並阻礙了新興市場（經濟限制是主要促進因素）的收入成長。

此外，這些經濟限制阻礙了對缺乏標準生物標記患者的識別，因為此類病例所需的全面檢測往往費用高昂。在價格敏感地區擴大業務規模的困難正在減緩市場發展，並阻礙高品質診斷解決方案的更廣泛普及。國際藥物經濟與結果研究協會 (ISPOR) 2025 年的數據凸顯了這一問題，報告顯示，在低收入和中等收入國家，類風濕性關節炎患者的平均年度直接治療費用為每位患者 523 美元至 2,838 美元，這凸顯了廣泛應用所面臨的巨大經濟障礙。

市場趨勢

隨著遠距風濕病學和遠端監測工具的興起，疾病管理正從間歇性的醫院就診轉向透過數位平台進行持續追蹤。透過使用智慧型手機應用程式記錄關節發炎和症狀波動的即時數據，這些技術能夠實現及時的治療調整，並為臨床醫生提供客觀的長期洞察。這種變革彌合了患者日常生活與醫療監管之間的鴻溝，從而改善了醫療服務的提供。根據 Medscape 於 2025 年 3 月報道，DETECTRA 行動應用程式在分散式醫療環境中展現了數位工具的巨大潛力，其在區分腫脹關節和非腫脹關節方面達到了 84% 的診斷準確率。

另一個重要趨勢是開發專門針對血清陰性患者的新型生物標記物，這些標記物針對的是那些在類風濕因子等標準指標檢測中呈陰性的患者，從而填補了診斷空白。研究人員已經確定了可用於確診血清陰性類風濕關節炎的替代自體抗體，這可以避免因標準檢測結果不確定而導致的治療延誤。根據2025年4月發表在《AiArthritis》雜誌上的一篇報導，在後來發展為血清陰性類風濕關節炎的患者中，有42%的人檢測到了抗RA 33生物標記。這項進展顯著提高了對這一亞組的篩檢能力，而該亞組患者歷來難以診斷。

目錄

第1章概述

第2章：調查方法

第3章執行摘要

第4章：客戶心聲

第5章：全球類風濕性關節炎診斷檢測市場展望

  • 市場規模及預測
    • 按金額
  • 市佔率及預測
    • 檢測類型（血清學檢測{紅血球沉積速率（ESR）、類風濕因子（RF）、抗環瓜氨酸肽（抗CCP）、抗核抗體（ANA）、尿酸、其他檢測}、RA治療效果監測檢測{水楊酸鹽濃度、肌肉酵素檢測（CPK、醛縮酶）、肌酸酐檢測}）
    • 依最終用戶（診斷檢查室、私人檢查室、公共檢查室、門診手術中心）分類
    • 按地區
    • 按公司（2025 年）
  • 市場地圖

第6章：北美類風濕性關節炎診斷檢測市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 北美洲：國別分析
    • 美國
    • 加拿大
    • 墨西哥

第7章：歐洲類風濕性關節炎診斷測試市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 歐洲：國別分析
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙

第8章：亞太地區類風濕性關節炎診斷檢測市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 亞太地區：國別分析
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲

第9章：中東和非洲類風濕性關節炎診斷檢測市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 中東與非洲：國別分析
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非

第10章：南美洲類風濕性關節炎診斷測試市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 南美洲：國別分析
    • 巴西
    • 哥倫比亞
    • 阿根廷

第11章 市場動態

  • 促進因素
  • 任務

第12章 市場趨勢與發展

  • 併購
  • 產品發布
  • 近期趨勢

第13章 全球類風濕性關節炎診斷檢測市場：SWOT分析

第14章：波特五力分析

  • 產業競爭
  • 新進入者的潛力
  • 供應商的議價能力
  • 顧客權力
  • 替代品的威脅

第15章 競爭格局

  • Abbott Laboratories Inc.
  • Siemens Healthineers AG
  • Thermo Fisher Scientific Inc.
  • Exagen Inc.
  • Augurex Life Sciences Corp.
  • Danaher Corporation
  • Bio-Rad Laboratories, Inc.
  • Tulip Diagnostics（P）Ltd
  • Boditech Med Inc.
  • Getein Biotech, Inc.

第16章 策略建議

第17章：關於研究公司及免責聲明

簡介目錄
Product Code: 24335

The Global Rheumatoid Arthritis Diagnostic Tests Market is projected to expand from USD 3.31 Billion in 2025 to USD 4.72 Billion by 2031, registering a CAGR of 6.09%. This market encompasses laboratory assays and imaging technologies designed to detect autoimmune markers and assess joint inflammation, playing a critical role in confirming diagnoses and monitoring disease progression. Growth is largely fueled by the rising incidence of autoimmune conditions and an expanding geriatric population, alongside a clinical emphasis on early intervention to prevent irreversible joint damage. As reported by the Arthritis Foundation, approximately 1.3 million adults in the United States were affected by rheumatoid arthritis in 2025, highlighting the demand for effective screening tools.

Market Overview
Forecast Period2027-2031
Market Size 2025USD 3.31 Billion
Market Size 2031USD 4.72 Billion
CAGR 2026-20316.09%
Fastest Growing SegmentSerology Test
Largest MarketNorth America

The market faces significant hurdles, however, due to the high cost of sophisticated diagnostic instruments in developing nations. The expense associated with specialized assays and advanced imaging systems limits their widespread adoption in regions with constrained financial resources. This economic barrier is further compounded by the challenge of diagnosing patients who do not exhibit standard biomarkers, creating a substantial impediment to global market expansion. Consequently, the difficulty in implementing comprehensive testing in cost-sensitive areas remains a critical restraint for the industry.

Market Driver

A primary catalyst for the diagnostic tests market is the escalating global prevalence of rheumatoid arthritis, which drives the need for accurate and scalable screening methodologies. As autoimmune disorder rates climb, healthcare infrastructure faces increasing pressure to establish diagnostic frameworks capable of identifying the disease at its onset. This urgency is intensified by the severe health and economic consequences of delayed diagnosis within the working-age population. According to a June 2025 article in PLOS, there were 11.88 million rheumatoid arthritis cases among working-age individuals globally in 2021, underscoring the vital necessity for accessible serological and imaging tests to manage this growing patient cohort effectively.

Concurrently, the market is being transformed by breakthroughs in immunoassay technologies and the discovery of novel biomarkers, which enhance sensitivity and facilitate personalized care. The integration of artificial intelligence and machine learning with conventional diagnostics is enabling more accurate predictions of therapeutic responses and better clinical decision-making. For example, Scipher Medicine announced in June 2025 the validation of its AI-driven RA Response Calculator using data from nearly 1,500 patients to improve treatment evaluation. This technological momentum is supported by significant investments, such as Aqtual's receipt of $31 million in Series B funding in 2025 to commercialize its precision medicine solutions.

Market Challenge

The prohibitive cost of advanced diagnostic tools in developing economies represents a major obstacle to the expansion of the rheumatoid arthritis diagnostic tests market. Specialized assays and modern imaging equipment often carry price tags that exceed the budgetary limits of healthcare systems in these regions, forcing providers to depend on basic clinical assessments rather than precise screening methods. This disparity in affordability restricts the sales volume of advanced test kits, thereby limiting revenue growth in emerging markets where financial constraints are a dominant factor.

Furthermore, these economic limitations hinder the identification of patients who lack standard biomarkers, as the comprehensive testing required for such cases is frequently too expensive. The inability to scale operations in price-sensitive regions stalls market progress and prevents broader access to premium diagnostic solutions. Data from the International Society for Pharmacoeconomics and Outcomes Research in 2025 highlighted this issue, reporting that average annual direct costs for managing rheumatoid arthritis in low- and middle-income countries ranged between USD 523 and USD 2,838 per patient, emphasizing the severe financial barriers to widespread adoption.

Market Trends

The rise of Tele-Rheumatology and remote monitoring tools is shifting disease management from episodic clinical visits to continuous tracking via digital platforms. By leveraging smartphone applications to record real-time data on joint inflammation and symptom variability, these technologies enable timely treatment adjustments and offer clinicians objective, longitudinal insights. This evolution bridges the gap between daily patient life and medical supervision, enhancing care delivery. As noted by Medscape in March 2025, the DETECTRA mobile app achieved an 84% diagnostic accuracy in distinguishing swollen from non-swollen joints, demonstrating the potential of digital tools in decentralized healthcare settings.

Another significant trend is the development of novel biomarkers specifically targeting seronegative patients, addressing diagnostic voids for those who test negative for standard indicators like Rheumatoid Factor. Researchers are identifying alternative autoantibodies to confirm the disease in its seronegative form, which helps prevent treatment delays associated with inconclusive standard tests. According to an April 2025 article by AiArthritis, the anti-RA 33 biomarker was found in 42% of patients who subsequently developed seronegative rheumatoid arthritis. This advancement significantly improves screening capabilities for a subgroup that has historically been difficult to diagnose.

Key Market Players

  • Abbott Laboratories Inc.
  • Siemens Healthineers AG
  • Thermo Fisher Scientific Inc.
  • Exagen Inc.
  • Augurex Life Sciences Corp.
  • Danaher Corporation
  • Bio-Rad Laboratories, Inc.
  • Tulip Diagnostics (P) Ltd
  • Boditech Med Inc.
  • Getein Biotech, Inc.

Report Scope

In this report, the Global Rheumatoid Arthritis Diagnostic Tests Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Rheumatoid Arthritis Diagnostic Tests Market, By Test Type

  • Serology Test
  • Monitoring RA Treatment Efficiency Tests

Rheumatoid Arthritis Diagnostic Tests Market, By End User

  • Diagnostic Laboratories
  • Private Laboratories
  • Public Laboratories
  • Ambulatory Surgical Centers

Rheumatoid Arthritis Diagnostic Tests Market, By Region

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Rheumatoid Arthritis Diagnostic Tests Market.

Available Customizations:

Global Rheumatoid Arthritis Diagnostic Tests Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Rheumatoid Arthritis Diagnostic Tests Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Test Type (Serology Test {Erythrocyte Sedimentation Rate (ESR), Rheumatoid Factor (RF), Anti-cyclic Citrullinated Peptide (anti-CCP), Antinuclear Antibody (ANA), Uric Acid, Other Tests}, Monitoring RA Treatment Efficiency Tests {Salicylate Level Count, Muscle Enzyme Tests (CPK, Aldolase), Creatinine Test})
    • 5.2.2. By End User (Diagnostic Laboratories, Private Laboratories, Public Laboratories, Ambulatory Surgical Centers)
    • 5.2.3. By Region
    • 5.2.4. By Company (2025)
  • 5.3. Market Map

6. North America Rheumatoid Arthritis Diagnostic Tests Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Test Type
    • 6.2.2. By End User
    • 6.2.3. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Rheumatoid Arthritis Diagnostic Tests Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Test Type
        • 6.3.1.2.2. By End User
    • 6.3.2. Canada Rheumatoid Arthritis Diagnostic Tests Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Test Type
        • 6.3.2.2.2. By End User
    • 6.3.3. Mexico Rheumatoid Arthritis Diagnostic Tests Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Test Type
        • 6.3.3.2.2. By End User

7. Europe Rheumatoid Arthritis Diagnostic Tests Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Test Type
    • 7.2.2. By End User
    • 7.2.3. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Rheumatoid Arthritis Diagnostic Tests Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Test Type
        • 7.3.1.2.2. By End User
    • 7.3.2. France Rheumatoid Arthritis Diagnostic Tests Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Test Type
        • 7.3.2.2.2. By End User
    • 7.3.3. United Kingdom Rheumatoid Arthritis Diagnostic Tests Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Test Type
        • 7.3.3.2.2. By End User
    • 7.3.4. Italy Rheumatoid Arthritis Diagnostic Tests Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Test Type
        • 7.3.4.2.2. By End User
    • 7.3.5. Spain Rheumatoid Arthritis Diagnostic Tests Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Test Type
        • 7.3.5.2.2. By End User

8. Asia Pacific Rheumatoid Arthritis Diagnostic Tests Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Test Type
    • 8.2.2. By End User
    • 8.2.3. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China Rheumatoid Arthritis Diagnostic Tests Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Test Type
        • 8.3.1.2.2. By End User
    • 8.3.2. India Rheumatoid Arthritis Diagnostic Tests Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Test Type
        • 8.3.2.2.2. By End User
    • 8.3.3. Japan Rheumatoid Arthritis Diagnostic Tests Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Test Type
        • 8.3.3.2.2. By End User
    • 8.3.4. South Korea Rheumatoid Arthritis Diagnostic Tests Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Test Type
        • 8.3.4.2.2. By End User
    • 8.3.5. Australia Rheumatoid Arthritis Diagnostic Tests Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Test Type
        • 8.3.5.2.2. By End User

9. Middle East & Africa Rheumatoid Arthritis Diagnostic Tests Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Test Type
    • 9.2.2. By End User
    • 9.2.3. By Country
  • 9.3. Middle East & Africa: Country Analysis
    • 9.3.1. Saudi Arabia Rheumatoid Arthritis Diagnostic Tests Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Test Type
        • 9.3.1.2.2. By End User
    • 9.3.2. UAE Rheumatoid Arthritis Diagnostic Tests Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Test Type
        • 9.3.2.2.2. By End User
    • 9.3.3. South Africa Rheumatoid Arthritis Diagnostic Tests Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Test Type
        • 9.3.3.2.2. By End User

10. South America Rheumatoid Arthritis Diagnostic Tests Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Test Type
    • 10.2.2. By End User
    • 10.2.3. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Rheumatoid Arthritis Diagnostic Tests Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Test Type
        • 10.3.1.2.2. By End User
    • 10.3.2. Colombia Rheumatoid Arthritis Diagnostic Tests Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Test Type
        • 10.3.2.2.2. By End User
    • 10.3.3. Argentina Rheumatoid Arthritis Diagnostic Tests Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Test Type
        • 10.3.3.2.2. By End User

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global Rheumatoid Arthritis Diagnostic Tests Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. Abbott Laboratories Inc.
    • 15.1.1. Business Overview
    • 15.1.2. Products & Services
    • 15.1.3. Recent Developments
    • 15.1.4. Key Personnel
    • 15.1.5. SWOT Analysis
  • 15.2. Siemens Healthineers AG
  • 15.3. Thermo Fisher Scientific Inc.
  • 15.4. Exagen Inc.
  • 15.5. Augurex Life Sciences Corp.
  • 15.6. Danaher Corporation
  • 15.7. Bio-Rad Laboratories, Inc.
  • 15.8. Tulip Diagnostics (P) Ltd
  • 15.9. Boditech Med Inc.
  • 15.10. Getein Biotech, Inc.

16. Strategic Recommendations

17. About Us & Disclaimer